Drug Type Live biotherapeutic products |
Synonyms SER-262 |
Target- |
Mechanism Bacteria replacements, Gastrointestinal microbiome modulators |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Clostridium difficile infection | Phase 1 | US | 01 Aug 2016 | |
Clostridium Infections | Discovery | CH | - |